(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Best 10 Innovation Advancements of the Year - 2Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- 3Figure out How to Put resources into Lab Precious stones
- 4Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- 5This Luxurious Thermal Spa In Italy Is Perfect For A Relaxing Escape While Visiting Milan
- Journalist reported killed in the Gaza Strip
- Audits of 6 European Busssiness Class Flights
- Israel strikes south Lebanon after first direct talks in decades
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- NASA's Perseverance Mars rover could break the record for miles driven on another planet
- Dave Coulier reveals he has tongue cancer, his 2nd diagnosis in a year, after beating non-Hodgkin lymphoma
- 10 Hints for an Effective New employee screening
- Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
- 'I carried my wife's body for an hour and a half' - BBC hears stories of protesters killed in Iran
